PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.32%
Cash & equivalents declining -7.32% while Biotechnology shows -0.54% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-7.32%
Cash + STI yoy growth 1.25-1.5x the Biotechnology median of -5.28%. Mohnish Pabrai might see a strategic surplus if short-term returns make sense.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.49%
Exceeding 1.5x Biotechnology median of -3.69%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-6.31%
Current assets growth ≥ 1.5x the Biotechnology median of -4.10%. Joel Greenblatt sees a potential liquidity edge if well allocated.
-8.93%
PP&E growth ≥ 1.5x the Biotechnology median of -3.00%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.62%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
-7.75%
≥ 1.5x the Biotechnology median of -1.60%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
-6.35%
≥ 1.5x the Biotechnology median of -3.80%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5.18%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
5.07%
Above 1.5x Biotechnology median of 1.65%. Jim Chanos suspects potential working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.44%
50-75% of Biotechnology median of -0.69%. Mohnish Pabrai notes relatively contained yoy growth.
No Data
No Data available this quarter, please select a different quarter.
0.54%
Above 1.5x Biotechnology median of 0.27%. Jim Chanos suspects an alarming rise in overall leverage.
No Data
No Data available this quarter, please select a different quarter.
-1.80%
0.5-0.75x Biotechnology median of -3.33%. Guy Spier is cautious about weaker retention vs. peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.26%
≥ 1.5x Biotechnology median of -5.41%. Joel Greenblatt sees stronger equity growth vs. peers.
-6.35%
≥ 1.5x Biotechnology median of -3.80%. Joel Greenblatt sees more aggressive expansions than peers.
No Data
No Data available this quarter, please select a different quarter.
-8.07%
Above 1.5x Biotechnology median of -0.04%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
7.30%
Above 1.5x Biotechnology median 2.33%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.